Your patient walks in thrilled about their weight loss. They’ve lost 40 pounds in six months using Ozempic. Their energy is better. Their health markers have improved. But they’re distressed. Their face looks gaunt. They have sunken cheeks, hollowed eyes, and deeper wrinkles. They look older, not healthier. This is Ozempic face. And you’re seeing it more and more in your practice. As GLP-1 medications become mainstream for weight loss, the demand for aesthetic treatment of Ozempic face grows rapidly. The global obesity medication market is expected to reach £84.5 billion by 2030. That means a growing population of patients needing your expertise to restore facial volume and youthfulness after rapid weight loss. This guide covers everything you need to know about treating Ozempic face, from understanding the mechanism to consultation strategies to comprehensive treatment protocols.
Table of Contents
Ozempic face describes the gaunt, hollowed, prematurely aged appearance that develops after rapid weight loss from GLP-1 medications like Ozempic, Wegovy, or Mounjaro. It’s not a medical diagnosis. It’s a cosmetic concern that reflects specific structural changes in the face.
The term was popularised by cosmetic dermatologist Dr Paul Jarrod Frank after treating many patients experiencing these changes. While the media has sensationalised the term, the clinical reality is straightforward. When patients lose significant weight rapidly, their facial fat decreases quickly. Skin cannot shrink at the same rate. The result is a volume-depleted face with loose, sagging skin and prominent wrinkles.
What makes Ozempic face different from normal weight loss ageing is the speed. Patients typically experience dramatic weight loss within 6 to 12 months. Clinical trials for semaglutide (STEP trials) showed average weight loss of approximately 15 to 17 percent of body weight over 68 weeks. Tirzepatide (SURMOUNT trials) showed higher figures, with some patients losing 20 to 22 percent. Weight loss varies significantly between individuals and medications. This rapid change means patients can look older almost overnight.
Importantly, Ozempic face isn’t unique to Ozempic. Any rapid weight loss from any cause produces similar facial changes. Gastric bypass surgery, extreme dieting, or rapid weight loss from other medications can all cause Ozempic face. The medication itself isn’t the culprit. The speed and scale of weight loss is.
Ozempic doesn’t specifically target facial fat. Instead, it causes overall body fat loss through appetite suppression and slowed gastric emptying. The face has fat. So facial fat decreases along with body fat. But the face has unique structural characteristics that make fat loss particularly visible.
Understanding the mechanism helps you counsel patients effectively. Your face is maintained by several structures. Bone provides the underlying framework. Ligaments provide tension and support. Discrete fat pads maintain volume and shape. Skin provides elasticity and appearance. Over decades, normal ageing gradually reduces all of these. GLP-1 therapy accelerates part of this process.
Your face contains two main types of facial fat. Buccal fat sits between your cheekbones and jawline. Subcutaneous fat sits directly under your skin. When patients lose weight rapidly, these fat pads shrink quickly. Unlike gradual weight loss where skin has time to adjust, rapid loss leaves excess skin with insufficient volume to fill it.
The result is hollowed cheeks, sunken temples, under-eye hollowing, and a gaunt appearance. Patients report their face looks deflated or ‘caved in’.
This is the factor most articles about Ozempic face miss. Research shows that 25 to 40 percent of weight lost on GLP-1 medications comes from lean muscle mass, not fat. Your face contains over 20 muscles. When you lose weight, you lose facial muscle too. Less muscle combined with less fat means the face loses structural support.
This muscle loss is particularly significant in women. Studies show women lose more total weight than men on GLP-1 medications, and therefore more muscle. Older adults are also at higher risk, as they have lower muscle reserves to begin with.
Rapid weight loss depletes collagen and elastin, the proteins that keep skin firm and elastic. This happens because rapid weight loss often involves inadequate protein intake. Patients on Ozempic may struggle to eat enough calories and protein to support skin health.
Additionally, the dramatic fat loss outpaces the skin’s ability to shrink and retract. The skin becomes thin, crepe-like, and loses its natural plumpness and glow.
Multiple GLP-1 medications on the market cause facial changes. It’s not Ozempic-specific. Understanding which medications your patients use helps you anticipate their concerns and tailor your treatment approach.
Ozempic is the brand name for semaglutide prescribed for type 2 diabetes. Wegovy is the same medication approved specifically for weight loss. Both cause Ozempic face with similar severity. STEP trial data shows average weight loss of 15 to 17 percent body weight over 68 weeks, though individual results vary considerably.
Tirzepatide is a newer dual-action GLP-1 agonist that activates both GLP-1 and GIP pathways. Mounjaro is approved for type 2 diabetes and Zepbound for weight loss. SURMOUNT trial data shows tirzepatide produces higher average weight loss than semaglutide — some patients losing 20 to 22 percent of body weight. Patients on Mounjaro or Zepbound may therefore experience more pronounced facial changes and need a more involved treatment approach.
Liraglutide (Saxenda) is another GLP-1 agonist approved for weight loss. While less commonly used than semaglutide, it also causes facial changes with rapid weight loss.
Being able to recognise and describe Ozempic face helps you conduct better consultations. Patients often can’t articulate exactly what’s changed. They know they look older but don’t understand why. Your anatomical knowledge helps you explain the specific changes you observe.
This is where you differentiate from competitors. Your consultation approach directly impacts treatment outcomes and patient satisfaction. Understanding your patient’s emotional state, weight loss journey, and goals is critical.
Your patient has achieved something genuinely impressive. They’ve lost significant weight and their health has improved. But they feel betrayed by their reflection. They look older, not healthier. Many healthcare providers dismiss Ozempic face concerns, telling patients ‘you’re healthier, that’s what matters.’ This is poor counsel. Your validation of their concern immediately builds trust.
Start your consultation by acknowledging both their achievement and their concern. Say something like: ‘You’ve done amazing work losing this weight. Your health has improved significantly. But it’s completely valid to also want your face to reflect how you feel inside. We can address this.’ This builds rapport and sets realistic expectations.
This is crucial information that most practitioners skip. Ask directly: How much weight have you lost? Over what timeframe? Are you still losing or have you stabilised? Do you plan to lose more? This determines your entire treatment approach. If your patient still has significant weight loss planned, aggressive filler treatment now would be wasted. If they’ve stabilised, more comprehensive treatment is appropriate.
Ask which medication they’re taking and whether they plan to continue long-term. Also discuss Ozempic rebound. Many patients don’t know that stopping GLP-1 medication often leads to weight regain within months to a year. Explain that any volumisation you add might need adjustment if they regain weight.
This is where you outperform most practitioners. Many jump straight to filler injection. This is a mistake. The order of treatment is as important as what you treat with. Proper sequencing produces dramatically better results.
Think of Ozempic face as a three-layer problem: deteriorated skin quality, depleted volume, and weakened structural support. Expert practitioners understand these are interconnected. Treating them out of order produces poor results. Treating them in the correct sequence — skin first, volume second, structure third — produces excellent, natural-looking results.
This is non-negotiable. Do not inject fillers into thin, dehydrated, depleted skin. The filler will not integrate properly. It can look lumpy, feel unnatural, and the poor skin quality will still make the face look aged despite the added volume. Phase 1 involves rebuilding skin quality over 4 to 8 weeks before any volume restoration.
Timeline: 4 to 8 weeks of Phase 1 before progressing to Phase 2. This investment creates a far better foundation for everything that follows.
Only after skin quality has improved should you begin volume restoration. Phase 2 involves strategic filler placement to restore natural facial contours.
Traditional hyaluronic acid fillers work well for Ozempic face. For longer-lasting, more natural results, consider biostimulatory fillers. Sculptra stimulates collagen production gradually over months, restoring volume while improving skin quality simultaneously. This suits Ozempic face patients well, as it mirrors the gradual improvement these patients need rather than an immediate large volume change.
On volume: Ozempic face typically requires significantly more filler than you would use for a standard ageing patient. Many practitioners underestimate this. Set realistic cost expectations with patients early in the consultation.
Patients still actively losing weight on GLP-1 medications present a specific anatomical consideration that is easy to overlook: rapid changes in facial fat pad volume can alter the relative position of underlying vascular structures.
As subcutaneous fat diminishes, vessels that were previously cushioned by tissue may sit closer to the surface. Anatomical landmarks you’d normally use to estimate vessel depth may be less reliable in patients with significant ongoing fat loss. This is particularly relevant in the glabella, temporal region, and nasolabial area.
For patients who are still actively losing weight, extra caution is warranted in high-risk injection zones. Practical considerations include:
This is a further reason why waiting for weight stabilisation before high-volume treatment is the safest approach. The anatomical landscape is a moving target in patients with ongoing significant weight loss.
Once skin quality is restored and volume replaced, address structural laxity. This often involves non-surgical skin tightening or, in severe cases, surgical referral.
In cases of severe skin laxity, referral for surgical facelift or fat grafting may be more appropriate. Understanding when to refer is as important as the treatments you offer.
Timeline: Phase 3 typically begins 3 to 4 months after initiating Phase 1, once you can assess results from skin restoration and filler placement.
Ozempic rebound is a critical concept many practitioners don’t discuss with patients. When patients stop taking GLP-1 medications, weight regain often occurs within months to a year. Some patients regain most or all of the weight they lost.
This directly affects your aesthetic treatment. If a patient regains weight, facial fat returns. The fillers you’ve carefully placed may now look overdone or unnatural. Patients need to understand this possibility upfront.
Some practitioners recommend delaying aggressive filler treatment until the patient has been at a stable weight for at least 6 months. This gives you a better baseline to work from and reduces the risk of over-correction if weight changes.
No. It may improve if weight is regained or if skin adjusts over time. Younger patients with better elasticity are more likely to see natural improvement. Older patients less so. Cosmetic treatments provide meaningful improvement regardless of age.
Avoid aggressive volumisation until weight stabilises. Begin Phase 1 skin quality treatments while the patient continues losing weight. Be especially cautious with high-risk injection zones in patients with active ongoing fat loss, as vessel anatomy may be less predictable. Transition to more comprehensive filler treatment once weight has been stable for 2 to 3 months.
Significantly more than a standard ageing patient. Underestimating the volume required is one of the most common practitioner mistakes with this cohort. Set realistic cost expectations with patients early in the consultation.
You should not attempt Ozempic face treatment without solid grounding in facial anatomy, filler technique, and complications management. These are complex cases involving higher volumes in multiple anatomical zones, often in patients with altered facial tissue characteristics. The complications course is essential preparation for any practitioner working with high-volume filler cases.
Ozempic face treatment represents a significant shift in aesthetic practice. As GLP-1 medications continue to gain prevalence in weight management, practitioners with expertise in treating the facial consequences of rapid weight loss will be increasingly sought out. The clinical opportunity is substantial, the patient demand is genuine, and the scope for delivering meaningful results is enormous. Practitioners who invest in a broad skill set — covering skin boosters, advanced fillers, biostimulators, and complications management – will be best placed to serve this evolving patient cohort. A strong foundation through structured aesthetic training across these disciplines puts you in the best position to deliver safe, excellent outcomes for these patients.
£1106.00 (incl. VAT)
£1106.00 (incl. VAT)
From: £2101.00 (incl. VAT)
£3213.00 (incl. VAT)
£1106.00 (incl. VAT)
£1106.00 (incl. VAT)
From: £1730.00 (incl. VAT)
£1480.00 (incl. VAT)
From: £1730.00 (incl. VAT)
From: £1730.00 (incl. VAT)
If you’re looking to keep your skills sharp or revisit techniques on your own schedule, our Online Botox and Dermal Filler Training Courses on DermaHub is here to support your aesthetic journey. With easy-to-follow video tutorials, expert insights, and flexible access, you can learn anytime, anywhere. It’s a great way to stay updated, refresh your knowledge, and deepen your understanding, with CPD-accredited content designed to fit around your lifestyle.
Where Aesthetics meets Longevity
Complete the form to receive a personalised consultation on pathways and package deals tailored to your goals.
Receive a free starter kit upon enrolment
